Background: In patients with rheumatoid arthritis in remission, a disease activity-driven tapering of adalimumab or etanercept relying on progressive injection spacing has not been shown to be equivalent to a maintenance strategy at full dose in terms of disease activity in the Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS) trial. Objectives: To evaluate the costeffectiveness of such a spacing strategy based on the data of the STRASS trial. Methods: This is a cost-utility analysis of the STRASS trial, a French multicenter 18-month equivalence randomized openlabel controlled trial that included patients at stable dose for at least 1 year, in remission for at least 6 months. Effectiveness was assessed in quality-adjusted life-years (QALYs). Costs involved in the study period were assessed from a payer perspective. The decremental cost-effectiveness ratio (DCER) was calculated in the complete cases sample (n ¼ 98). Several sensitivity analyses were conducted and the impact of missing data on DCER estimate was investigated. An acceptability analysis was performed. Results: In the spacing arm, TNF-blockers were stopped for 34.1% of the patients, tapered for 43.2%, and maintained at full dose for 18.2%. The spacing strategy was associated with less QALYs gain (mean difference of À0.158; 95% confidence interval [CI] À0.085 to À0.232) and reduced costs (mean difference of À€8,440; 95% CI À6,507 to À10,212). The estimated DCER of the spacing strategy over the maintenance at full dose was €53,417 saved per QALY lost (95% CI 32,230 to 104,700). Conclusions: The spacing strategy appears cost-effective, but the acceptability of such a QALY loss reported to the cost avoided remains to be evaluated, because no consensual threshold has been determined for willingness to accept as compared with willingness to pay.
Introduction
Remission is the widely accepted objective for patients with rheumatoid arthritis (RA), thanks to an early and dynamic stepup therapeutic strategy based on conventional synthetic and/or biologic disease-modifying antirheumatic drugs (csDMARDs/ bDMARDs) [1] [2] [3] [4] [5] . Once this objective is achieved, treatment down-titration could be considered to lower the burden that DMARD could represent for patients, to potentially reduce DMARD adverse events-some of them being dose-dependent [6] [7] [8] [9] [10] [11] -and more generally to limit patient overtreatment [12, 13] . In addition, in the case of bDMARDs, step-down strategies could result in substantial cost savings for society [13, 14] .
Although bDMARD discontinuation has been associated with limited risk of maintaining remission or low disease activity at 1 year in established RA [15] [16] [17] [18] , progressive dose reduction appears more relevant from a clinical point of view. An observational study [14] assessed progressive down-titration of infliximab over 1 year and showed that down-titration was feasible in 45% of patients, with a mean dose reduction of 60%. Meanwhile, two randomized controlled trials showed that the risks of relapse and structural damage progression were not significantly different after 1 year of follow-up, with etanercept (ETA) maintained at either full dose (50 mg weekly) or half dose (25 mg weekly) [19, 20] .
Alternatively, a disease activity-driven tapering of bDMARD could rely on progressive injection spacing, which could represent a preferred option for patients versus reduced dosing of each injection. Two trials have investigated such an option with slightly different results. In the Dose REduction Strategy of Subcutaneous TNF inhibitors (DRESS) trial [21] , injection spacing was associated with an increase in incidence of short-lived flares. Nevertheless, administration of intramuscular high-dose steroids and return to the previous injection interval rapidly controlled the disease, and the spacing strategy was thus noninferior to maintenance regimen in terms of persisting flares. The second study was the Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS) trial in which the spacing strategy-based only on injections spacing out or in (depending on disease activity, without rescue with high-dose steroid)-was considered not equivalent to the maintenance, with a slight increase in disease activity and more relapses [22] (although when relapses occurred, they were successfully managed by spacing injections in). Nonetheless, in the STRASS trial, no excess risk of structural damage progression with the spacing strategy compared with full-dose maintenance was evidenced. It indicates that the spacing strategy could constitute a meaningful opportunity to identify the lowest efficacious dose at a risk of relapse but no risk of irreversible damage for the patient [22] . For all these reasons, the cost-effectiveness of the spacing strategy deserves to be further investigated.
Thus, the present study is an economic evaluation based on the data of the STRASS trial, for which a cost-utility analysis comparing the two aforementioned strategies was preplanned as a secondary analysis.
Methods

Study Design
The STRASS trial was a multicenter 18-month equivalence randomized controlled trial following the Prospective Randomized Open Blinded End-Point methodology [23] , which compared two therapeutic strategies in patients with established RA who achieved clinical remission with subcutaneous injection of the TNF-blocker ETA or adalimumab (ADA) in 22 rheumatology hospital departments in France and 1 department in Monaco. The primary objective of the trial was to demonstrate the equivalence of down-titrating ETA or ADA by progressively spacing injections (S-arm), and maintaining full-regimen therapy (M-arm), in terms of disease activity [22] .
Patients were randomly assigned in a 1:1 ratio to one of the two strategies. The randomization list was generated by using a computer-generated sequence with blocks of variable and undisclosed size, stratified by center or TNF-blocker (i.e., ETA or ADA). Treatment allocation was concealed to patients, research staff, and clinical staff until randomization by using an Internet-based randomization module (Cleanweb s , Telemedecine Technologies S.A.S., Boulogne-Billancourt, France). Patients and clinical staff could not be further masked to treatment allocation because a sham intervention was not feasible. Patients were, however, unaware of study hypothesis and clinical staff were unaware of aggregate outcomes during the study. The outcome assessor for the 28-joint disease activity score (DAS28; primary outcome) and x-ray readers were masked to treatment allocation.
The study and all the related documents were approved for all centers by an ethics review board (CPP Ile de France VI) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practices. A standardized information sheet was given to eligible patients to explain that different therapeutic strategies have been proposed for patients with RA in remission without formal evaluation so far, which necessitated the conduct of trials such as STRASS. Written informed consent was obtained from all patients before their participation in the trial.
The present cost-utility analysis was developed according to guidelines for economic evaluations edited by the French Authority in Health [24] (Haute Autorité de Santé). Nonetheless, we used the payer-health insurance (national public or private)-perspective. The time horizon was 18 months, which was the follow-up period of the study.
Patients
From September 2008 to January 2011, we included patients who were 18 years or older, had a diagnosis of RA according to the 1987 American College of Rheumatology classification criteria, and received subcutaneous injections of ETA or ADA at a standard and stable dosage (i.e., 50 mg weekly for ETA and 40 mg every other week for ADA) for at least 1 year as monotherapy or combined with a stable conventional DMARD (methotrexate or leflunomide) for at least 6 months. Patients receiving conventional DMARDs and prednisone (r5 mg/d) concomitantly to TNFblockers could continue these therapies at a strictly stable dose throughout the study period.
Patients needed to be in clinical remission according to the DAS28 (i.e., DAS28 r 2.6) for at least 6 months with no structural damage progression seen on hand and foot x-rays in the year before inclusion according to the treating rheumatologist.
Noninclusion criteria were of contraindications to TNF-blocker therapy maintenance, prednisone use of more than 5 mg/d, planned surgical intervention or pregnancy within the 18-month study period, women of childbearing age without efficacious contraception, history of cancer, diagnosis of an autoimmune disorder other than RA, nonaffiliation with the French social security system, and presence of factors preventing informed consent or protocol adherence (e.g., inability to communicate in the French language, mental incapacity, and guardianship).
Finally, all included patients underwent clinical examination and gave their signed informed consent to be in the trial.
Interventions
In the M-arm (maintenance), patients continued to receive TNFblocker subcutaneous injections at the standard full regimen.
The S-arm (spacing) used a disease activity-driven approach to taper bDMARD, on the basis of a predefined algorithm (Fig. 1 ) Fig. 1 - Step-down algorithm for spacing subcutaneous injections of TNF-blockers. ADA, adalimumab; DAS, disease activity score; ETA, etanercept; RA, rheumatoid arthritis.
that progressively spaced out subcutaneous injections according to the DAS28 score.
In case of RA relapse among M-arm patients or S-arm step 0 (full dose) patients, changes in therapy were at the discretion of the rheumatologist, but patient follow-up continued till the end of the study.
Data Collection
Comprehensive sociodemographic and disease characteristics as well as clinical and biological parameters were collected at the time of inclusion and every 3 months thereafter. During followup, visits were scheduled every 3 months for 18 months. RA clinical and biological parameters and medication were collected at each visit. Radiography of hands and feet was performed at baseline and at 18 months.
Effectiveness and Cost Assessment
Effectiveness was measured by means of quality-adjusted lifeyears (QALYs). Utilities used to estimate QALYs were assessed at baseline and every 6 months using a French validated version of the three-level EuroQol five-dimensional questionnaire (EQ-5D-3L) [25] and French value set [26] . To adjust for baseline differences between the two arms in health state, adjusted QALYs were estimated by regression-based adjustment as proposed by Manca et al. [27] .
The global impression of the patients on their health state was also assessed. Patients were asked at baseline and at the end of the follow-up whether they found their health state to be at least acceptable (using the external anchors from the patient acceptable symptomatic state [28] ).
For direct costs, we assessed medical consumption according to the OMERACT reference case for economic assessments [29, 30] . Drugs consumption was assessed at each visit of the study every 3 months. For ETA or ADA consumption, the main bDMARDs of the study, individual costs were obtained by summing all subcutaneous injections recorded within the study period multiplied by the price of an injection listed in the last revision of the 2014 French drug dictionary (Vidal s ). For other drugs (other bDMARDs or csDMARDs, low dose of prednisone, anti-inflammatory drugs, and painkillers), a standard daily price multiplied by the number of days the treatment was taken was applied. Outpatient medical doctors or health professional consultations, biologic or imaging workups, occurrence of emergency room visits, hospitalizations, and inpatient care were assessed every 6 months using the Stanford Cost Assessment Questionnaire [31, 32] . Individual costs were obtained by multiplying the frequency of use of each item within the study period by the tariffs listed in the last 2014 revision of the national Classification of Medical Procedures ( Classification Commune des Actes Médicaux) and of the national Classification of Biological Tests (Nomenclature des Actes de Biologie Médicale) for medical doctor/health professional visits and imaging procedures and for biologic workups, respectively. Hospitalizations were analyzed on the basis of the International Classification of Diseases, 10th Revision, main diagnosis, using the 2014 Diagnosis Related Groups reference list. Costs were elicited on the basis of the national Diagnosis Related Groups tariff list (Groupes Homogènes de Séjour).
Productivity loss was limited to sick leave days. They were based on national average daily wages according to age, as provided by the French National Institute of Statistics and Economics Studies (Institut National de la Statistique et des Études Économiques).
All costs were expressed in 2014 euros and were discounted at a 4% annual rate according to the French Authority in Health guidelines [24] .
Statistical Analyses
The M-arm was the reference strategy. The primary cost-utility analysis was conducted using a complete cases analysis sample, that is, restricted to patients for whom all data on costs and outcomes were available along the 18-month follow-up period.
We tested differences in costs and outcomes between the two strategies using parametric or nonparametric tests (χ 2 test, Fisher exact test for count data, McNemar χ 2 test, and two-sample
Mann-Whitney Wilcoxon test) as appropriate. The difference in adjusted QALYs between the two arms was longitudinally tested by means of a linear mixed model and post hoc two-by-two comparisons using relevant contrasts with P values adjusted for multiple comparisons according to the Holm-Bonferroni stepdown procedure [33] . A decremental cost-effectiveness ratio (DCER) was calculated [34] by dividing the difference in costs by the difference in QALYs between the groups.
To deal with uncertainty in DCER estimation, 5000 DCERs using 5000 samples generated by nonparametric bootstrap were computed to plot a cost-effectiveness plane and to estimate a confidence interval at a 95% level (95% CI) [34] .
Sensitivity analyses were performed on the assessment of QALYs. Thus, QALYs were also estimated using utilities derived from the French validated version of the six-dimensional health state short form (SF-6D) [35, 36] . Because a French value set is not available yet for the SF-6D, the UK value set was used [37] . Thus, QALYs were also estimated with utilities from the EQ-5D with UK value set [38] to allow comparability of the results.
Sensitivity analyses were performed on costs by decreasing the cost of each subcutaneous injection of ETA or ADA down to 70% of the current cost (to account for a plausible decrease in ETA or ADA prices in the near future in France).
The impact of missing data [39] on the results was investigated for costs and outcomes. An imputed DCER was estimated by means of multiple imputations by chained equations (MICE) [40, 41] (30 data sets generated [42] ).
To help decide which strategy should be promoted, two indicators were used. First, the probability of each strategy to be cost-effective for different willingness-to-accept (WTA) thresholds was computed [34] . Second, the incremental net monetary benefit (iNMB) per patient for the S-arm was estimated for different WTA thresholds in euros per QALY, by multiplying the WTA threshold with the difference in QALYs and then subtracting the difference in costs. This provides an estimate of the net amount of money saved, when the possible loss of QALY is corrected for, using different WTA thresholds per QALY [34] .
All statistical hypothesis tests were performed with a 5% type I error. All analyses were performed using R 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) [43] .
Results
The whole trial sample consisted of 64 patients in the S-arm and 73 patients in the M-arm. Data on costs and QALYs were complete for the 18-month follow-up period for 98 patients (71.5% of the whole trial sample): 44 patients (68.7%) in the S-arm and 54 patients (74.0%) in the M-arm (Fig. 2) . In the complete cases sample, 48 patients received ADA and 50 patients received ETA with 77 in combination with a csDMARD and 21 as monotherapy. The main baseline characteristics of patients are presented in Table 1 .
Spacing Feasibility and Acceptability
In the S-arm, at the 15-to 18-month period of follow-up, 8 patients (18.2%) were receiving TNF-blocker injections at full dose
(step 0). In all, 34 patients (77.2%) had spaced TNF-blocker injections: 12 (27.3%) were receiving spaced injections corresponding to step 3, 5 (11.4%) to step 2, and 2 (4.5%) to step 1, whereas 15 (34.1%) had completely discontinued TNF-blocker treatment (step 4). In the S-arm, bDMARD treatment remained unchanged except for 2 (4.5%) patients who discontinued it because of loss of efficacy.
Between baseline and the end of follow-up, the proportion of patients who found their health state at least acceptable dropped from 95.3% to 83.7% in the S-arm (À11.6%; P ¼ 0.06), whereas it dropped from 100.0% to 90.6% in the M-arm (À9.4%; P ¼ 0.02). This difference of evolution between the two therapeutic strategies was not found to be statistically significant (P ¼ 0.42). Table 2 and Fig. 3 ). At 18 months, the mean difference between the two therapeutic strategies was À0.158 QALYs (95% CI À0.086 to À0.232) (P o 0.001) ( Table 2 and Fig. 3 ). This mean difference in QALYs was also found to be statistically significant at 12 months of follow-up (P ¼ 0.001) but was not evidenced as significant at 6 months (P ¼ 0.15). At 18 months, this mean difference would be estimated to be À0.057 (P o 0.001) and À0.153 (P o 0.001) when using utilities derived from the SF-6D or the EQ-5D, both with the UK value set (Table 3) . At 18 months of follow-up, mean total costs were €12,452 Ϯ €6,175 (median €10,930; IQR €7,897-€14,788) in the S-arm and €20,892 Ϯ €1,388 (median €20,612; IQR €20,301-€21,096) in the M-arm. The cost of the treatment by ETA or ADA represented 81.0% and 92.8% of the total cost in the S-arm and the M-arm, respectively. The mean cost difference between the two arms was À€8,440 (95% CI À€6,507 to À€10,212) in favor of the S-arm ( Table 2 ). The health resource use breakdown is presented in Appendix Table 1 , with the related costs presented in Appendix 
Effectiveness and Costs
DCER, Acceptability Analysis, and Sensitivity Analyses
The DCER of the spacing over the maintenance strategy was estimated to be €53,417 saved per QALY lost (95% CI €32,230-€104,700) ( Table 2 ). This DCER would be estimated to be €55,163 and €148,070/QALY when using utilities derived from the EQ-5D or the SF-6D, both with the UK value set ( Table 3) .
The 5000 bootstrapped replications (Fig. 4A) showed that in all the 5000 replications, the spacing strategy resulted in QALY loss along with cost savings. The probability of the spacing strategy to be cost-effective was 0.99 and 0.61 for WTA compensation for QALY loss thresholds at €30,000 and €50,000, respectively (Fig. 4B) . That is, if a decision maker is willing to accept a loss in QALYs to free resources for other allocations, there is a 99% or 61% chance that he or she chooses the spacing strategy if what is wanted is €30,000 or €50,000, respectively, in compensation for the loss of a QALY. The iNMB of bDMARD, biological disease-modifying antirheumatic drug; CI, confidence interval; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DCER, decremental cost-effectiveness ratio; IQR, interquartile range; QALY, quality-adjusted life-year. * Percentage of total costs.
the spacing strategy is shown in Figure 4C . For WTA thresholds at €30,000 and €50,000, the mean iNMB was estimated to be €3,738 (95% CI €477-€6,779) and €589 (95% CI À€3,972-€4,894), respectively. Sensitivity analyses with lower ADA or ETA drug prices showed a decrease in the DCER. With 30% lower drug prices, the DCER would be €35,759/QALY (Table 3) .
Missingness on costs and/or QALYs was found to be associated neither with the intervention nor with the evolution of DAS28 during follow-up. Missingness was also not found to be associated with most of the baseline characteristics (see Appendix Table 3 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2017.01.005).
Thus, the missing data mechanism was not assumed to be "missing not at random," but rather "conditionally dependent missing completely at random," or "missing at random" at worst [39, 44] . After MICE imputations, the DCER was estimated to be €46,261/ QALY (mean difference in costs of À€8,327 and mean difference of À0.180 QALYs).
Discussion
In this study, spacing TNF-blocker injections among patients with established RA in remission was found to be less effective than a maintenance strategy at full dose (QALY loss) after 18 months of follow-up. Nonetheless, if a decrease in the proportion of patients who found their health state acceptable was observed during follow-up, it was observed in both arms in a magnitude that was not evidenced as different between the two arms, with most patients finding their health state acceptable at the end of follow-up. Moreover, the spacing strategy was associated with a substantial cost reduction. Therefore, the DCER of the spacing strategy was estimated to be €53,417 saved per QALY lost. In addition, the spacing strategy was found to be the strategy with the highest probability of being cost-effective for WTA compensation for QALY loss threshold at €50,000.
Thus, the present study addresses one of the most difficult questions relative to cost-effectiveness assessment: Is it acceptable to lower the economic burden of an innovative therapy if it is associated with a QALY loss, even though this loss is not substantial for patients and more importantly reversible? Such a question is key and hardly avoidable in the present economic context in which the funding of therapeutic innovation is a challenge for all health care payers over the world. Recently, an article showed that the increase in insurance premiums or worker contributions was approximately sixfold higher than the inflation rate in the United States over the 2000 decade, quasiexclusively explained by the dramatic increase in drug costs [45] .
Till now, health economics assessments have often focused on incremental cost-effectiveness ratio (ICER), that is, to determine to what extent a given health care system or society could ADA, adalimumab; DCER, decremental cost-effectiveness ratio; EQ-5D-3L, three-level EuroQol five-dimensional questionnaire; ETA, etanercept; QALY, quality-adjusted life-year; SF-6D, six-dimensional health state short form.
accept to fund a new compound relative to the additional expected health gain enabled by its reimbursement [34] . Nevertheless, it appears nowadays that the health market growth could not continue indefinitely in a very constrained economic environment, which refers to the concept of "degrowth" developed by certain philosophers [46] . In the traditional health economic plan, it corresponds to a move from the northeast quadrant to the southwest quadrant (Fig. 3A) , that is, from an ICER to a DCER. In the first case, it corresponds to a willingness-to-pay question ("What would we be willing to pay to get more health gain?") for which more or less consensual thresholds have been proposed [32, 47] . The latter case deals with a WTA question ("What would we be willing to accept as a money compensation to lose some health?") for which only a few studies have been performed because of the innate reluctance of people to lose [48] . Thus, results from cost-effectiveness evaluation that lie in the southwest quadrant often challenge researchers and policymakers in terms of decision making. Indeed, they are difficult to translate easily in a language that helps interpretability. Moreover, no consensual DCER thresholds have been proposed. Some could argue that DCER and ICER thresholds should be identical if the goal is to maximize societal health [49] . If we apply this reasoning in this study, then a decision maker who is willing to accept QALY loss to free resources should accept the spacing strategy if what is wanted is to free €30,000 to €50,000 for the loss of a QALY. Nonetheless, we acknowledge that there are still differing views on the symmetry, or not, of DCER and ICER thresholds [50] . In addition, those difficulties are even more emphasized in France, where no consensual thresholds for ICER are currently used by French health authorities. Nonetheless, despite those difficulties, reporting such results is of paramount importance to reduce publication bias and to inform decision makers about all possible outcomes. The present study has some limitations. In the STRASS trial, the DCER has been estimated to be €53,417/QALY. In the DRESS study [21] , the first results of an economic evaluation identified a much higher DCER: around €390,000 saved per QALY lost [51] . This striking difference could be related, in part, to the fact that in the DRESS study as opposed to the STRASS trial, patients received high-dose steroids in case of relapse, which could have dramatically reduced QALY loss.
Another limitation was the strong impact of the QALY assessment method on DCER estimates. In this study, using UK population norms, the estimated DCER was largely higher when using the SF-6D instead of the EQ-5D-3L. The low correspondence of utility estimations when using different multi-attribute utility instruments (MAUIs) is well known [52] , with still no consensus on the most appropriate MAUIs to choose [53] . In a recent study, it was estimated that this low correspondence can be partly attributed to differences in scales of each MAUI (the range of utilities predicted by the EQ-5D-3L is 1.59, whereas it is 0.797 with the SF-6D) but mostly to differences in the descriptive systems (the EQ-5D-3L assumes 5 dimensions and describes 243 health states, whereas the SF-6D assumes 6 dimensions and describes 18,000 health states) [53] . These differences may partly explain the lower mean difference in QALYs between the two therapeutic strategies reported in this study when using the SF-6D instead of the EQ-5D-3L. Indeed, when using the SF-6D, patients may have more options to report mild to moderate deviations of their health state from perfect health and therefore may have a lesser probability to report an extreme health state.
The last limitation of the study was the proportion of missing data for costs and QALYs that can have an impact on DCER estimate. Nonetheless, as missingness was found to be associated neither with the intervention nor with the evolution of DAS28 during follow-up or with most of the baseline characteristics, it appeared to be reasonable to investigate the impact of missing data on DCER estimate by means of MICE. The imputed DCER was estimated to be €46,261/QALY (mean difference in costs of À€8,327 and mean difference of À0.180 QALYs), close to the estimate of the complete cases analysis. Therefore, it seems that the impact of missing data could have been only a mild reduction of the difference in QALYs between the two therapeutic strategies.
Our study also had several strengths. First, besides DCER estimates, information about patient acceptability of health state had been collected. With the patient acceptable symptomatic state assessment, it appeared clearly that although the spacing strategy was genuinely associated with a QALY loss compared with the maintenance strategy, most patients continued to consider their health state acceptable. This information is clearly important and complementary to the WTA question. In addition, the structural damage assessment showed that spacing was not associated with an increased risk of irreversible joint damage [22] , which indicates a possibility for patients to return to their previous health states over the long-term. Nevertheless, the cost-effectiveness outcome of the spacing strategy has to be confirmed in longer term studies. Indeed, on one hand, spacing injections needs to be sustainable to be beneficial in costs over the long-term. On the other hand, the current short time horizon (combined with the sample size) can have affected the possibility to capture rare adverse events associated with bDMARDs, which could have been detrimental for the assessment of the costeffectiveness of the spacing strategy.
Conclusions
Treatment tapering has been shown to be relevant from a clinical point of view in patients with RA having achieved sustained remission. From an economic point of view, such a strategy is associated with a DCER of about €50,000 saved per QALY lost.
